R. Kate Kelley, MD
At the University of California, San Francisco School of Medicine, R. Kate Kelley, MD, contributes to research focused on improving outcomes for patients with hepatocellular carcinoma.
The trial: This was a phase III study that included 707 patients who received sorafenib and had disease progression after at least one systemic therapy; the patients were randomly assigned to receive cabozantinib, a tyrosine kinase inhibitor, or a placebo.
The results: Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than treatment with placebo.
The impact: More options for patients. In January 2019, the U.S. Food and Drug Administration approved cabozantinib for patients with hepatocellular carcinoma who have been treated with sorafenib. Based upon results from trials of cabozantinib in hepatocellular carcinoma and rationale for combination with immunotherapy, an international, randomized phase III trial of cabozantinib plus atezolizumab vs standard sorafenib is now ongoing.
The work of nine researchers who have previously received funding from Conquer Cancer is featured in the 2020 ASCO Clinical Cancer Advances. Visit CONQUER.ORG for more details.
© 2020. American Society of Clinical Oncology. All rights reserved.
